Connor Clark & Lunn Investment Management Ltd. Has $1.24 Million Stock Position in Sotera Health (NASDAQ:SHC)

Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Sotera Health (NASDAQ:SHC - Free Report) by 128.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 90,332 shares of the company's stock after acquiring an additional 50,870 shares during the period. Connor Clark & Lunn Investment Management Ltd.'s holdings in Sotera Health were worth $1,236,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of SHC. Wealth Enhancement Advisory Services LLC raised its holdings in Sotera Health by 2.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,940 shares of the company's stock valued at $711,000 after buying an additional 1,047 shares in the last quarter. GAMMA Investing LLC raised its holdings in Sotera Health by 37.5% during the fourth quarter. GAMMA Investing LLC now owns 4,109 shares of the company's stock valued at $56,000 after buying an additional 1,121 shares in the last quarter. Blue Trust Inc. raised its holdings in Sotera Health by 164.3% during the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock valued at $25,000 after buying an additional 1,140 shares in the last quarter. True Wealth Design LLC bought a new position in Sotera Health during the third quarter valued at about $32,000. Finally, Amalgamated Bank raised its holdings in Sotera Health by 3.4% during the fourth quarter. Amalgamated Bank now owns 72,715 shares of the company's stock valued at $995,000 after buying an additional 2,368 shares in the last quarter. 91.03% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

SHC has been the topic of several recent research reports. Barclays cut their target price on Sotera Health from $17.00 to $16.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. The Goldman Sachs Group assumed coverage on Sotera Health in a research note on Friday, December 6th. They issued a "neutral" rating and a $14.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $15.92.

Sotera Health Stock Performance

Shares of Sotera Health stock traded down $0.07 during trading on Friday, reaching $11.90. The company's stock had a trading volume of 1,623,348 shares, compared to its average volume of 1,164,798. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The business's fifty day moving average price is $12.94 and its 200-day moving average price is $14.14. The firm has a market cap of $3.37 billion, a price-to-earnings ratio of 47.60 and a beta of 1.92. Sotera Health has a one year low of $10.71 and a one year high of $17.08.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.